Eisai, Biogen Launch Subcutaneous LEQEMBI Pen in Japan

MT Newswires Live11-13

Eisai (TYO:4523) and Biogen have launched the LEQEMBI Pen, a subcutaneous formulation of lecanemab, in Japan following its listing on Japan's National Health Insurance drug price list on Friday.

Japan becomes the second country after the United States to launch the subcutaneous version of LEQEMBI, which received approval as a new route of administration in September, according to a Tokyo bourse filing on Friday.

The autoinjector formulation allows either patient self-administration or administration by a care partner using two pens, with a total of 500 mg, once weekly.

With this launch, LEQEMBI treatment now offers a once-weekly subcutaneous option alongside the existing intravenous administration every two weeks in a medical facility.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment